Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Neurology

What Are the Stages of ALS Progression? King's & MiToS

At a Glance

Doctors stage ALS progression using the ALSFRS-R questionnaire along with the King's Staging System, which tracks how symptoms spread across the body, and the MiToS System, which measures the loss of daily functional independence.

Your doctor uses specific staging systems to track how ALS is progressing and to help you plan for future care needs. Unlike cancer, where stages describe the size and spread of a tumor, ALS stages describe how the disease affects your daily life and which parts of your body are involved. To do this, doctors primarily rely on a questionnaire called the ALS Functional Rating Scale-Revised (ALSFRS-R), alongside two specific staging frameworks: the King’s Staging System and the MiToS System.

The ALSFRS-R: The Foundation of ALS Staging

The ALSFRS-R is a 12-item questionnaire that measures your physical function across four key areas: gross motor skills (like walking), fine motor skills (like using your hands), bulbar function (speech and swallowing), and breathing [1].

Each item is scored from 0 to 4, giving a maximum total score of 48. Higher scores indicate better physical function. While the ALSFRS-R is excellent for tracking day-to-day functional changes [1], a single total score doesn’t clearly define a “stage” of the disease [2]. To translate these scores into a clearer picture of your disease progression, doctors use the King’s and MiToS systems.

The King’s Staging System: Tracking Anatomical Spread

The King’s Staging System focuses on how ALS spreads across different regions of your body—specifically the bulbar (head and neck), upper limbs (arms), and lower limbs (legs) [3]. It is particularly sensitive to the early and middle stages of the disease [4].

This system breaks the disease into stages based on the number of body regions involved and the need for specific medical interventions [5]. It’s important to remember that progression is highly individual—some people may stay in one stage for a long time, and the timeline varies from person to person.

  • Stage 1: Symptoms have appeared in one body region [3].
  • Stage 2: Symptoms have spread to a second body region [3].
  • Stage 3: Symptoms involve a third body region [3].
  • Stage 4: This stage is reached when medical interventions are needed to support vital functions. It is divided into Stage 4A, where a feeding tube (gastrostomy) may be recommended, and Stage 4B, where non-invasive breathing support (like BiPAP or NIV) may be chosen [3][5].
  • Stage 5: This final stage represents the end of life, where the focus shifts entirely to comfort and palliative or hospice care [6].

The King’s system helps your care team anticipate when you might want to consider interventions like a feeding tube or breathing support, allowing you to discuss and plan for these milestones proactively rather than in an emergency [7][8].

The MiToS Staging System: Tracking Loss of Independence

The Milano-Torino (MiToS) system takes a different approach. Instead of looking at which body regions are affected, it maps specific answers from your ALSFRS-R questionnaire to track the loss of functional independence [9].

MiToS is especially useful for providing clarity in the later stages of the disease [10]. It looks at four critical areas of independence: walking/self-care, swallowing, communicating, and breathing [11].

  • Stage 0: You have symptoms, but you have not lost independence in any of the four areas [11].
  • Stage 1: You have lost independence in one area [11].
  • Stage 2: You have lost independence in two areas [11].
  • Stage 3: You have lost independence in three areas [11].
  • Stage 4: You have lost independence in all four areas [11].
  • Stage 5: This final stage represents the end of life, emphasizing comfort and quality of life through palliative care [11].

How These Systems Work Together

Doctors use these tools together to get a complete picture of your health. The King’s system helps predict the timeline for physical spread and the need for supportive equipment [12][13]. Meanwhile, the MiToS system focuses on your daily autonomy and what kind of caregiving support you might need [4].

For example, you might be at King’s Stage 3 because symptoms have appeared in your legs, arms, and speech, but you might only be at MiToS Stage 1 if you have only lost full independence in walking. Together, these systems ensure that your medical management adapts to your evolving needs, giving you and your family time to plan for the future [7].

Common questions in this guide

How do doctors measure ALS progression?
Doctors primarily use a 12-item questionnaire called the ALS Functional Rating Scale-Revised (ALSFRS-R) to measure physical function. They then apply the King's Staging System and the MiToS System to translate these scores into clear stages of disease progression.
What is the King's Staging System for ALS?
The King's system tracks how ALS symptoms spread across different regions of your body, including the head and neck, arms, and legs. It is especially useful for predicting when you might need interventions like a feeding tube or breathing support.
What does the MiToS System measure in ALS?
The MiToS system tracks the loss of functional independence in daily life. It specifically focuses on four critical areas: walking or self-care, swallowing, communicating, and breathing.
What is Stage 4 of ALS?
In the King's system, Stage 4 occurs when medical interventions are needed to support vital functions. This is divided into Stage 4A, where a feeding tube is recommended, and Stage 4B, which involves non-invasive breathing support.
Does everyone progress through ALS stages at the same rate?
No, ALS progression is highly individual. Some people may stay in a single stage for a long time, and the overall timeline of the disease varies significantly from person to person.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my most recent ALSFRS-R scores, how would you describe my current stage using the King's and MiToS systems?
  2. 2.What specific signs or symptoms should we be watching for that would indicate I am moving to a new stage?
  3. 3.When should we start discussing the potential need for interventions like a feeding tube or non-invasive ventilation?
  4. 4.What is my current total ALSFRS-R score, and how has it changed since my last visit?
  5. 5.Based on the King's system, what proactive steps should we be planning for now?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (13)
  1. 1

    Adaptation to Turkish and Reliability Study of the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R).

    Koç F, Balal M, Demir T, et al.

    Noro psikiyatri arsivi 2016; (53(3)):229-233 doi:10.5152/npa.2016.11334.

    PMID: 28373799
  2. 2

    Evaluating ALSFRS-R as an indicator of disease milestones and functional independence: An observational study of US neurologists and their patients with amyotrophic lateral sclerosis.

    Mehdiyoun NF, Wright J, Robinson RL, et al.

    Journal of the neurological sciences 2026; (481()):125732 doi:10.1016/j.jns.2026.125732.

    PMID: 41520654
  3. 3

    A proposed staging system for amyotrophic lateral sclerosis.

    Roche JC, Rojas-Garcia R, Scott KM, et al.

    Brain : a journal of neurology 2012; (135(Pt 3)):847-52 doi:10.1093/brain/awr351.

    PMID: 22271664
  4. 4

    The utility of ALS staging systems in a multi-ethnic patient cohort.

    Abdul Aziz NA, Toh TH, Loh EC, et al.

    Amyotrophic lateral sclerosis & frontotemporal degeneration 2021; (22(5-6)):341-349 doi:10.1080/21678421.2021.1893336.

    PMID: 33726578
  5. 5

    Staging model for amyotrophic lateral sclerosis in Singapore.

    Tay YT, H Chai JY, Shekh Jabin KB, Ang K

    Singapore medical journal 2022; (63(7)):371-375 doi:10.11622/smedj.2021001.

    PMID: 33472335
  6. 6

    Cervical spinal cord atrophy in amyotrophic lateral sclerosis across disease stages.

    Nigri A, Dalla Bella E, Ferraro S, et al.

    Annals of clinical and translational neurology 2023; (10(2)):213-224 doi:10.1002/acn3.51712.

    PMID: 36599092
  7. 7

    Patient-based evidence for amyotrophic lateral sclerosis prognostic health communication: "the clock is ticking…how long do I have?"

    Genuis SK, Luth W, Adams B, Johnston WS

    Amyotrophic lateral sclerosis & frontotemporal degeneration 2026; (27(3-4)):301-311 doi:10.1080/21678421.2025.2589782.

    PMID: 41264881
  8. 8

    Clinical Staging of Amyotrophic Lateral Sclerosis in Chinese Patients.

    Chen X, Wei QQ, Chen Y, et al.

    Frontiers in neurology 2018; (9()):442 doi:10.3389/fneur.2018.00442.

    PMID: 29971035
  9. 9

    The MITOS system predicts long-term survival in amyotrophic lateral sclerosis.

    Tramacere I, Dalla Bella E, Chiò A, et al.

    Journal of neurology, neurosurgery, and psychiatry 2015; (86(11)):1180-5 doi:10.1136/jnnp-2014-310176.

    PMID: 25886781
  10. 10

    Comparison of the King's and MiToS staging systems for ALS.

    Fang T, Al Khleifat A, Stahl DR, et al.

    Amyotrophic lateral sclerosis & frontotemporal degeneration 2017; (18(3-4)):227-232 doi:10.1080/21678421.2016.1265565.

    PMID: 28054828
  11. 11

    Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis.

    Chiò A, Hammond ER, Mora G, et al.

    Journal of neurology, neurosurgery, and psychiatry 2015; (86(1)):38-44 doi:10.1136/jnnp-2013-306589.

    PMID: 24336810
  12. 12

    Comparison Of King's Clinical Staging In Multinational Amyotrophic Lateral Sclerosis Cohorts.

    Balendra R, Jones AR, Al Khleifat A, et al.

    Amyotrophic lateral sclerosis & frontotemporal degeneration 2023; (24(1-2)):71-81 doi:10.1080/21678421.2022.2090847.

    PMID: 35852375
  13. 13

    Lower and upper motor neuron involvement and their impact on disease prognosis in amyotrophic lateral sclerosis.

    Zakharova MN, Abramova AA

    Neural regeneration research 2022; (17(1)):65-73 doi:10.4103/1673-5374.314289.

    PMID: 34100429

This page provides educational information about ALS staging and progression. It is not a substitute for professional medical advice, diagnosis, or treatment from your neurologist or care team.

Get notified when new evidence is published on Amyotrophic lateral sclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.